Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules

Nature Communications

Volumn 4, Issue , 2013, Pages

  Childs Disney, Jessica L ^a   Stepniak Konieczna, Ewa ^b   Tran, Tuan ^a,c   Yildirim, Ilyas ^d   Park, HaJeung ^a   Chen, Catherine Z ^e   Hoskins, Jason ^f   Southall, Noel ^e   Marugan, Juan J ^e   Patnaik, Samarjit ^e   Zheng, Wei ^e   Austin, Chris P ^e   Schatz, George C ^d   Sobczak, Krzysztof ^b   Thornton, Charles A ^f   Disney, Matthew D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c UNIVERSITY AT BUFFALO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA PRECURSOR; INSULIN RECEPTOR; MBNL1 PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN BINDING; RNA; RNA BINDING PROTEIN; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ARTICLE; COMPLEX FORMATION; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE CONTROL; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; MYOTONIC DYSTROPHY; PROTEIN RNA BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SPLICING; SPLICING DEFECT; ZINC FINGER MOTIF; ANIMAL; CHEMISTRY; DRUG EFFECTS; EXON; GENE SILENCING; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; MOLECULAR DOCKING; MOLECULAR GENETICS; MOLECULAR LIBRARY; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHARMACOLOGY; PLASMID; PROTEIN SYNTHESIS; THERAPEUTIC USE; CELL STRAIN HEK293; DRUG EFFECT; HELA CELL; PROTEIN BINDING;

ANIMALS; BASE SEQUENCE; EXONS; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MYOTONIC DYSTROPHY; PLASMIDS; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; RECEPTOR, INSULIN; RNA; RNA PRECURSORS; RNA SPLICING; RNA-BINDING PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84889102738     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3044     Document Type: Article

References (44)

1. Faustino, N. A. & Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev. 17, 419-437 (2003).
2. Savkur, R. S. et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am. J. Hum. Genet. 74, 1309-1313 (2004).
3. Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079-3088 (2004).
4. Fugier, C. et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat. Med. 17, 720-725 (2011).
5. Sellier, C. et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 29, 1248-1261 (2010).
6. Liquori, C. L. et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293, 864-867 (2001).
7. Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat. Struct. Mol. Biol. 17, 187-193 (2010).
8. Orengo, J. P., Ward, A. J. & Cooper, T. A. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann. Neurol. 69, 681-690 (2011).
9. Savkur, R. S., Philips, A. V. & Cooper, T. A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40-47 (2001).
10. Philips, A. V., Timchenko, L. T. & Cooper, T. A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737-741 (1998).
11. Charlet, B. N. et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45-53 (2002).
12. Mankodi, A. et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 10, 35-44 (2002).
13. Mastroyiannopoulos, N. P., Feldman, M. L., Uney, J. B., Mahadevan, M. S. & Phylactou, L. A. Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3′ untranslated region transcripts. EMBO Rep. 6, 458-463 (2005).
14. Amack, J. D., Paguio, A. P. & Mahadevan, M. S. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum. Mol. Genet. 8, 1975-1984 (1999).
15. Cardani, R., Mancinelli, E., Rotondo, G., Sansone, V. & Meola, G. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Eur. J. Histochem. 50, 177-182 (2006).
16. Chen, C. Z. et al. Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal. Bioanal. Chem. 402, 1889-1898 (2012).
17. Childs-Disney, J. L., Hoskins, J., Rzuczek, S. G., Thornton, C. A. & Disney, M. D. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem. Biol. 7, 856-862 (2012).
18. Chaires, J. B., Ragazzon, P. A. & Garbett, N. C. A competition dialysis assay for the study of structure-selective ligand binding to nucleic acids. Curr. Protoc. Nucleic Acid Chem. Chapter 8, 8.3.1-8.3.8 (2003).
19. Kumar, A. et al. Myotonic dystrophy type 1 RNA crystal structures reveal heterogeneous 1 x 1 nucleotide UU internal loop conformations. Biochemistry 50, 9928-9935 (2011).
20. Warf, M. B. & Berglund, J. A. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA 13, 2238-2251 (2007).
21. Lee, M. M., Pushechnikov, A. & Disney, M. D. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chem. Biol. 4, 345-355 (2009).
22. Mykowska, A., Sobczak, K., Wojciechowska, M., Kozlowski, P. & Krzyzosiak, W. J. CAG repeats mimic CUG repeats in the misregulation of alternative splicing. Nucleic Acids Res. 39, 8938-8951 (2011).
23. Ho, T. H. et al. Muscleblind proteins regulate alternative splicing. EMBO J. 23, 3103-3112 (2004).
24. Dansithong, W., Paul, S., Comai, L. & Reddy, S. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J. Biol. Chem. 280, 5773-5780 (2005).
25. Orengo, J. P., Bundman, D. & Cooper, T. A. A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res. 34, e148 (2006).
26. Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. & Berglund, J. A. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 18551-18556 (2009).
27. Paronetto, M. P., Achsel, T., Massiello, A., Chalfant, C. E. & Sette, C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J. Cell. Biol. 176, 929-939 (2007).
28. Pedrotti, S. et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J. 29, 1235-1247 (2010).
29. Charizanis, K. et al. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron 75, 437-450 (2012).
30. Wang, E. T. et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150, 710-724 (2012).
31. Jog, S. P. et al. RNA splicing is responsive to MBNL1 dose. PLoS ONE 7, e48825 (2012).
32. Holt, I. et al. Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. Genes Cells 12, 1035-1048 (2007).
33. Xiao, X. et al. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat. Struct. Mol. Biol. 16, 1094-1100 (2009).
34. Teplova, M. & Patel, D. J. Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. Nat. Struct. Mol. Biol. 15, 1343-1351 (2008).
35. 2 reveal a dynamic UU internal loop found in myotonic dystrophy type 1. Biochemistry 50, 599-601 (2011).
36. Cheng, K., Wang, X. & Yin, H. Small-molecule inhibitors of the TLR3/dsRNA complex. J. Am. Chem. Soc. 133, 3764-3767 (2011).
37. Parkesh, R. et al. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database & chemical similarity searching. J. Am. Chem. Soc. 134, 4731-4742 (2012).
38. Childs-Disney, J. L., Parkesh, R., Nakamori, M., Thornton, C. A. & Disney, M. D. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem. Biol. 7, 1984-1993 (2012).
39. Kumar, A. et al. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chem. Biol. 7, 496-505 (2012).
40. Sinha, J., Reyes, S. J. & Gallivan, J. P. Reprogramming bacteria to seek and destroy an herbicide. Nat. Chem. Biol. 6, 464-470 (2010).
41. Topp, S. & Gallivan, J. P. Emerging applications of riboswitches in chemical biology. ACS Chem. Biol. 5, 139-148 (2010).
42. Werstuck, G. & Green, M. R. Controlling gene expression in living cells through small molecule-RNA interactions. Science 282, 296-298 (1998).
43. Culler, S. J., Hoff, K. G. & Smolke, C. D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 330, 1251-1255 (2010).
44. Podvinec, M. et al. Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. J. Med. Chem. 53, 1483-1495 (2010).